Who is sponsoring NCT01099228?

NCT01099228 is sponsored by David Bushnell.

What condition does NCT01099228 study?

NCT01099228 studies Neuroendocrine Tumors.

What drugs are being tested in NCT01099228?

Interventions: 131-I MIBG and 111-In pentetreotide, 131-I MIBG and In-111 DOTATATE.

What is the status of NCT01099228?

NCT01099228 is currently COMPLETED.

Last reviewed 2016-07-19 · How we verify

Combination Targeted Radiotherapy in Neuroendocrine Tumors

NCT01099228 NA COMPLETED

The primary aim of this project is to determine, what fraction of individuals with neuroendocrine tumors would show substantially improved tumor dosimetry with combined agent therapy compared to "best" single agent therapy and determine the magnitude of the potential tumor radiation dose increase.

Details

Lead sponsor	David Bushnell
Phase	NA
Status	COMPLETED
Enrolment	2
Start date	2006-09
Completion	2015-07

Conditions

Neuroendocrine Tumors

Interventions

131-I MIBG and 111-In pentetreotide
131-I MIBG and In-111 DOTATATE

Primary outcomes

Dosimetry Results — 1 week after scan
Determine the patient specific bone marrow, kidney and tumor dosimetry results for each subject from the 2 groups will be used to calculate the optimal combination of administered activities for 131I-MIBG plus 90Y-DOTATOC (group 1) 131I-MIBG plus 177Lu-DOTATATE (group 2) and the resultant dose delivery to tumor from each combination

Countries

United States